title: [Outcomes of 104 children with B-cell non-Hodgkin lymphoma].
abstract: OBJECTIVE
  To analyze outcomes and prognostic factors of children with B-cell non-Hodgkin lymphoma (B-NHL).
  
  
  METHODS
  One hundred and four newly diagnosed B-NHL children were enrolled in protocol of B-NHL 2001. The statistics were performed by SPSS 13.0.
  
  
  RESULTS
  Of 104 children (79 males, the median age of 7.1 years), 60, 32 and 4 patients were diagnosed with Burkitt lymphoma, diffuse large B-cell lymphoma and unclassifiable B-cell lymphoma, respectively. Four patients were in stage Ⅰ, 27 stage Ⅱ, 55 stage Ⅲ and 18 stage Ⅳ; 1, 26 and 77 patients were allocated into R1, R2 and R3 risk groups, respectively. Three patients never got complete remission (CR), 9 patients relapsed after CR with the duration of relapse from 1 to 7 months after chemotherapy. The estimated 5-year EFS of 104 patients was (86.7 ± 3.5)%. Univariable analyses identified that risk factors for recurrence were of higher staging, elevated LDH, serum ferritin and poor early response. Age, sex, pathologic diagnosis, original tumor, bone or marrow involvement, C-MYC and risk group were not found to be associated with the risk of failure to treatment. Multivariable COX regression models confirmed serum ferritin as a significant independent prognostic marker.
  
  
  CONCLUSIONS
  B-NHL 2001 protocol was reasonable for B-NHL children. Higher staging, elevated LDH, serum ferritin and poor early response increased risk for recurrence.
authors.affiliation: Department of Hematology/Oncology, Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai 200127, China.
authors.forename: Qi-dong
authors.initials: QD
authors.lastname: Ye
authors.forename: Ci
authors.initials: C
authors.lastname: Pan
authors.forename: Hui-liang
authors.initials: HL
authors.lastname: Xue
authors.forename: Jing
authors.initials: J
authors.lastname: Chen
authors.forename: Min
authors.initials: M
authors.lastname: Zhou
authors.forename: Hua
authors.initials: H
authors.lastname: Jiang
authors.forename: Shu-hong
authors.initials: SH
authors.lastname: Shen
authors.forename: Yan-jing
authors.initials: YJ
authors.lastname: Tang
authors.forename: Jian-min
authors.initials: JM
authors.lastname: Wang
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D016393:Lymphoma, B-Cell / Q000175:diagnosis / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D011379:Prognosis; D011446:Prospective Studies; D016896:Treatment Outcome